M. Contoli (Ferrara (FE), Italy), A. Jensen (Roskilde, Denmark), L. Lahousse (Ghent, Belgium)
Association of cardiovascular risk with inhaled long-acting anti-muscarinic antagonists in COPD patients with impaired renal function Y. Cheng (Douliou, Taiwan), H. Peng (Douliou, Taiwan), Y. Chen (Douliou, Taiwan), C. Chen (Douliou, Taiwan)
| |
Evaluation of vasomotor substances in COPD patients V. Kapustnik (Kharkiv, Ukraine), O. Arkhipkina (Kharkiv, Ukraine)
| |
Systemic inflammatory profile of patients with acute coronary syndrome and concomitant COPD M. Contoli (Ferrara, Italy), M. Padovani (Ferrara, Italy), S. Soave (Ferrara, Italy), B. Palazzi (Ferrara, Italy), R. Pavasini (Ferrara, Italy), G. Campo (Ferrara, Italy), A. Papi (Ferrara, Italy)
| |
Can BODE index identify right ventricular dysfunction in COPD patients? P. Venishetty (chennai, India)
| |
Diurnal arterial stiffness in patients with chronic obstructive pulmonary disease of varying severity G. Dolishnyaya (Saratov, Russian Federation), N. Karoli (Saratov, Russian Federation), A. Rebrov (Saratov, Russian Federation)
| |
Determinants of aortic stiffness compared to level of obstruction and staging of COPD Ð. Ljubicic (Zagreb, Croatia), N. Tudoric (Zagreb, Croatia)
| |
Aortic stiffness in patients with COPD compared to two control groups of smokers and nonsmokers Ð. Ljubicic (Zagreb, Croatia), N. Tudoric (Zagreb, Croatia), D. Dilber (Zagreb, Croatia)
| |
Integrity of Membrane Cell as a Risk Factor of Longer Length of Stay in patients with Cardiopulmonary Disease D. González (Mexico city, Mexico), A. 1 Orea-Tejeda (Mexico city, Mexico), C. Chávez-Méndez (Mexico city, Mexico), G. Dávila-Said (Mexico city, Mexico), C. Olivo-Villalobos (Mexico city, Mexico), R. Sánchez-Santillán (Mexico city, Mexico), V. Peláez-Hernández (Mexico city, Mexico), K. Balderas-Muñoz (Mexico city, Mexico), R. Peréz-Padilla (Mexico city, Mexico), M. Rivera-Rodríguez (Mexico city, Mexico), L. Hernández-Urquieta (Mexico city, Mexico)
| |
Comorbidity of atherosclerotic diseases in COPD patients. V. Nevzorova (Vladivostok, Russian Federation), N. Zakharchuk (Vladivostok, Russian Federation), E. Kondrashova (Vladivostok, Russian Federation), E. Gonchar (Vladivostok, Russian Federation)
| |
Acute vascular diseases: Prompting admissions and readmissions in COPD patients R. Kochar (Delhi, India), V. Mittal (Delhi, India), A. Goel (Delhi, India), R. Dabas (Delhi, India)
| |
Acute cor pulmonale during acute exacerbations of COPD: a new phenotype? D. Boyer (Rouen, France), E. Artaud-Macari (Rouen, France), D. Schleifer (Rouen, France), D. Delacour (Rouen, France), Z. Djerada (Rouen, France), J. Dacher (Rouen, France), A. Cuvelier (Rouen, France)
| |
Evaluation of a new cardiac arrhythmias predictor in patients with COPD A. SAIDANE (TUNIS, Tunisia), J. Ben Ammar (TUNIS, Tunisia), M. Ben Hlima (TUNIS, Tunisia), S. Ouali (TUNIS, Tunisia), M. Mourali (TUNIS, Tunisia), B. Dhahri (TUNIS, Tunisia), S. Azzabi (TUNIS, Tunisia), H. Cherif (TUNIS, Tunisia), M. Baccar (TUNIS, Tunisia), H. Aouina (TUNIS, Tunisia)
| |
Safety of nebivolol and bisoprolol in patients (pts) with COPD and stable angina. O. Fesenko (Dnipro, Ukraine), K. Bogatska (Dnipro, Ukraine)
| |
Cardiovascular safety of fixed dose combination long acting bronchodilators in stable patients with Chronic Obstructive Pulmonary Disease. S. Ghosh (Leicester, United Kingdom), M. Bridge (Leicester, United Kingdom), N. Shahid (Leicester, United Kingdom), A. Jones (Leicester, United Kingdom), N. O'Kelly (Lincoln, United Kingdom)
| |
Utility of electrical bioimpedance by phase analysis to predict the type of heart failure in patients with COPD A. Orea-Tejeda (Mexico, Mexico), R. Sánchez-Santillán (Mexico, Mexico), D. González-Islas (Mexico, Mexico), C. Chávez Méndez (Mexico, Mexico), C. Olivo-Villalobos (Mexico, Mexico), G. Dávila-Said (Mexico, Mexico), L. Hernández-Urquieta (Mexico, Mexico), V. Peláez-Hernández (Mexico, Mexico), A. Velázquez-Montero (Mexico, Mexico), M. Rivera-Rodriguez (Mexico, Mexico), L. Castillo-Aguilar (Mexico, Mexico), K. Balderas-Muñoz (Mexico, Mexico)
| |
Platelet activity in patients with COPD and concomitant arterial hypertension K. Gashynova (Dnipro, Ukraine), O. Kovalenko (Dnipro, Ukraine), V. Rodionova (Dnipro, Ukraine), L. Glyniana (Dnipro, Ukraine)
| |
Safety and benefits of beta-blockers in chronic obstructive pulmonary disease: a review of current evidence and meta-analysis R. Villalobos (Manila, Philippines), I. Tan (Manila, Philippines), R. Divinagracia (Manila, Philippines)
| |
COPD patients require more health care than heart failure patients L. Lind (Linköping, Sweden), J. Lyth (Linköping, Sweden), D. Karlsson (Linköping, Sweden), A. WiréHn (Linköping, Sweden), L. Persson (Linköping, Sweden)
| |
Risk factors for asymptomatic atrial fibrillation in patients with COPD E. Samorukova (Moscow, Russian Federation), E. Leonova (Moscow, Russian Federation), T. Adasheva (Moscow, Russian Federation), V. Zadionchenko (Moscow, Russian Federation), A. Malyavin (Moscow, Russian Federation), S. Pavlov (Moscow, Russian Federation)
| |
Increased risk of atrial fibrillation in patients with acute exacerbation of chronic obstructive pulmonary disease and sinus rhythm A. Hemat (Duesseldorf, Germany), P. Müller (Duesseldorf, Germany), C. Jung (Duesseldorf, Germany), S. Krüger (Duesseldorf, Germany), S. Keymel (Duesseldorf, Germany)
| |